Comparative Analysis of Calprotectin and Helicobacter Pylori in the Faces and Interleukin-6 in the Blood of Patients with and without Covid-19 Before and After the Treatment
Keywords:
COVID-19, calprotectin, interleukin-6, Helicobacter pylori, rebamipide
Abstract
Of the 100 patients who were followed up, 60 were "relatively cured" of Covid-19 and 40 were uninfected. The levels of calprotectin, Helicobacter pylori and interleukin-6 in the blood, which were detected in their feces, were reliably higher in those who passed the coronavirus. At the next stage of the study, the patients of the first group were divided into 2 subgroups of 30 based on the complex treatments prescribed on the basis of the standard of treatment of the existing disease. The first subgroup was prescribed rebamipide as a combination therapy and compared with the other two groups. In the group that received rebamipide, compared to those that did not receive it, it was found that calprotectin, Helicobacter pylori and interleukin-6 in the blood were significantly reduced.
References
1. Chan K.H., Poon L.L., Cheng V.C., Guan Y., Hung I.F., Kong J., et al. Detection of SARS coronavirus in patients with suspected SARS. Emerg Infect Dis. 2004;10(2):294-9. https://doi.org/10.3201/eid1002.030610.
2. Grinevich VB, Kravchuk, AYu, Tkachenko EI, etc. Features of management of patients with gastroenterological pathology in the conditions of the COVID-19 pandemic. Experimental and clinical gastroenterology. 2020; 176.
3. Holshue M.L., DeBolt C., Lindquist S., Lofy K.H., Wiesman J., Bruce, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020 Mar 5;382(10):929-36. https://doi.org/10.1056/NEJMoa2001191.
4. Liang W., Feng Z., Rao S., Xiao O., Xue X., Lin Z., et al. Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus. Gut. 2020;69(6):1141-43. https://doi.org/10.1136/gutjnl-2020-320832.
5. Lu R., Zhao X., Li J., Niu P., Yang B., Wu H., et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395(10224):565-74. https://doi.org/1016/S0140-6736(20)30251-8.
6. Matysiak-Budnik T, Heyman M, Megraud F. Review article:rebamipide and the digestive epithelial barrier. Aliment Pharmacol Ther. 2003;18 (Suppl. 1):55-62. doi:10.1046/j.1365-2036.18.s1.6.x.
7. Pan L., Mu M., Ren H. G., Yang P., Sun Y. Wang R., et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol, 2020;115(5):766-73. https://doi.org/10.14309/ajg.0000000000000620.
8. Tang A., Tong Z.D., Wang H.L., Dai Y.X., Li K.F., Liu J.N., et al. Detection of novel coronavirus by RT-PCR in stool specimen from asymptomatic child, China. Emerg Infect Dis. 2020;26(6):1337-39. https://doi.org/10.3201/eid2606.200301.
9. Ungaro R.C., Sullivan T., Colombel J.-F., Patel G. What should gastroenterologists and patients know about COVID-19? Clin Gastroenterol Hepatol. 2020;18(7):1409-11. https://doi.org/10.1016/j.cgh2020.03.02.
10. Wu Y., Guo C., Tang L., Hong Z., Zhou J., Dong X., et al. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. Lancet Gastroenterol Hepatol 2020;5(5):434-35. https://doi.org/10.1016/S2468-1253(20)30083-2.
11. Xiao F., Tang M., Zheng X. Liu Y., Li X., Shan H. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology. 2020; 158(6):1831-33. https://doi.org/10.1053/j.gastro.2020.02.055.
12. Young B.E., Ong S.W.X., Kalimuddin S., Low J.G., Tan S.J., Loh J., et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA. 2020;323(15):1488-94. https://doi.org/10.1001/jama.2020.3204.
13. Zhang W., Du R.H., Li B., Xu D., Wang J., Li Z., Lin J. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect 2020;9(1):386-9. https://doi.org/10.1080/22221751.2020.1729071.
2. Grinevich VB, Kravchuk, AYu, Tkachenko EI, etc. Features of management of patients with gastroenterological pathology in the conditions of the COVID-19 pandemic. Experimental and clinical gastroenterology. 2020; 176.
3. Holshue M.L., DeBolt C., Lindquist S., Lofy K.H., Wiesman J., Bruce, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020 Mar 5;382(10):929-36. https://doi.org/10.1056/NEJMoa2001191.
4. Liang W., Feng Z., Rao S., Xiao O., Xue X., Lin Z., et al. Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus. Gut. 2020;69(6):1141-43. https://doi.org/10.1136/gutjnl-2020-320832.
5. Lu R., Zhao X., Li J., Niu P., Yang B., Wu H., et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395(10224):565-74. https://doi.org/1016/S0140-6736(20)30251-8.
6. Matysiak-Budnik T, Heyman M, Megraud F. Review article:rebamipide and the digestive epithelial barrier. Aliment Pharmacol Ther. 2003;18 (Suppl. 1):55-62. doi:10.1046/j.1365-2036.18.s1.6.x.
7. Pan L., Mu M., Ren H. G., Yang P., Sun Y. Wang R., et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol, 2020;115(5):766-73. https://doi.org/10.14309/ajg.0000000000000620.
8. Tang A., Tong Z.D., Wang H.L., Dai Y.X., Li K.F., Liu J.N., et al. Detection of novel coronavirus by RT-PCR in stool specimen from asymptomatic child, China. Emerg Infect Dis. 2020;26(6):1337-39. https://doi.org/10.3201/eid2606.200301.
9. Ungaro R.C., Sullivan T., Colombel J.-F., Patel G. What should gastroenterologists and patients know about COVID-19? Clin Gastroenterol Hepatol. 2020;18(7):1409-11. https://doi.org/10.1016/j.cgh2020.03.02.
10. Wu Y., Guo C., Tang L., Hong Z., Zhou J., Dong X., et al. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. Lancet Gastroenterol Hepatol 2020;5(5):434-35. https://doi.org/10.1016/S2468-1253(20)30083-2.
11. Xiao F., Tang M., Zheng X. Liu Y., Li X., Shan H. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology. 2020; 158(6):1831-33. https://doi.org/10.1053/j.gastro.2020.02.055.
12. Young B.E., Ong S.W.X., Kalimuddin S., Low J.G., Tan S.J., Loh J., et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA. 2020;323(15):1488-94. https://doi.org/10.1001/jama.2020.3204.
13. Zhang W., Du R.H., Li B., Xu D., Wang J., Li Z., Lin J. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect 2020;9(1):386-9. https://doi.org/10.1080/22221751.2020.1729071.
Published
2022-09-30
How to Cite
I., I. M. (2022). Comparative Analysis of Calprotectin and Helicobacter Pylori in the Faces and Interleukin-6 in the Blood of Patients with and without Covid-19 Before and After the Treatment. Central Asian Journal of Medical and Natural Science, 3(5), 218-222. https://doi.org/10.51699/cajmns.v3i5.1074
Section
Articles
